News
-
Researchers from the University of St. Andrews, the University of Edinburgh, and St. Jude’s Children’s Research Hospital have published data demonstrating that a nasal spray designed to prevent the influenza virus from binding with receptors… Read more . . .
-
Gateway Analytical is inviting anyone attending RDD 2014 in Fajardo, Puerto Rico to a special VIP event on the evening of May 5. Attendees are invited to join Gateway for a sunset sail on a… Read more . . .
-
Inhaled drug developer Prosonix has announced a global licensing agreement with Mylan for its generic versions of GSK’s Flixotide and Flovent fluticasone propionate MDIs for the treatment of asthma. The deal covers two Prosonix MDIs,… Read more . . .
-
Theravance has initiated a dose-ranging Phase 2b study of its TD-4208 long-acting muscarinic antagonist (LAMA), the company announced. The study will compare four different dosages of TD-4208 and placebo, all delivered once daily via jet… Read more . . .
-
Researchers from the Icahn School of Medicine at Mount Sinai have demonstrated that a single 50 mg dose of a ketamine nasal spray could alleviate depressive symptoms in patients with treatment-resistant major depressive disorder within… Read more . . .
-
Many of the attendees at the upcoming RDD meeting in Puerto Rico who stop by Team Consulting’s table to check out the company’s Occoris inhaler probably won’t realize that the Team staff with whom they… Read more . . .
-
Copley Scientific will launch several new cascade impactor accessories designed to meet requirements for testing of fluticasone propionate inhalation powder set out in a new USP monograph at RDD 2014, the company has said. The… Read more . . .
-
Submit abstracts for posters and podium presentations by August 15, 2014 at woolcock.org.au/isam2014abstracts/ Abstracts accpted for the conference will be published in the Journal of Aerosol Medicine and Pulmonary Drug Delivery. Read more . . .
-
According to Hovione, the United States Patent and Trademark Office (USPTO) has granted the company a patent for its XCAPs capsule-based dry powder inhaler. The European Patent Office granted the company a patent for the… Read more . . .
-
The FDA has extended the Prescription Drug User Fee Act (PDUFA) date for MannKind’s Afrezza inhaled insulin by three months, according to MannKind. The original date was April 15, 2014; the new date is July… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland